Profile data is unavailable for this security.
About the company
BioLife Sciences Inc. is a commercialization accelerator, licensor, and disruptive technologies for the healthcare, beauty, and food and beverage industry sectors. The Company’s core business develops, licenses and distributes antimicrobial products and disruptive technology. Its solutions include Antimicrobial Copper Air Filters, Copper-Infused Textiles and Copper Infused Fabric Pots. The Company's BioLife antimicrobial copper fabric filter acts as a layer of protection by trapping in bacteria and releasing clean air. BioLife Antimicrobial Copper-Infused Textiles kill viruses and bacteria on contact through preventative clothing and textiles designed to inhibit virus and bacteria reproduction and cross contamination before it starts. Its BioLife Copper Infused Fabric Pots provides plants a healthier home. The copper infusion allows the plants that grow in the pots with additional protections from harmful microbes which can harm plants.
- Revenue in USD (TTM)0.00
- Net income in USD-202.41k
- Incorporated2000
- Employees565.00
- LocationBiolife Sciences Inc2831 Saint Rose Parkway, Suite 200HENDERSON 89052United StatesUSA
- Phone+1 (702) 866-2500
- Websitehttps://www.biolifesciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biolife Sciences Inc | 0.00 | -202.41k | 3.18k | 565.00 | -- | -- | -- | -- | -1.56 | -1.56 | 0.00 | -0.2182 | 0.00 | -- | -- | -- | -15,392.40 | -- | -- | -- | -- | -- | -- | -- | -- | -1.60 | -- | -- | -100.00 | -- | 63.96 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
MML Investors Services LLCas of 31 Mar 2024 | 1.00k | 0.00% |
Wetzel Investment Advisors, Inc.as of 31 Mar 2024 | 337.00 | 0.00% |